Open Orphan has successfully raised capital in an oversubscribed fundraise
Open Orphan Plc has completed an equity placing to raise US$15.5 million to maximize available COVID-19 opportunities and testing.
Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Open Orphan comprises of two commercial specialist CRO services businesses: hVIVO and Venn Life Sciences, and has offices in London, Dublin, Paris and the Netherlands. The company is led by a management team with deep industry and financial experience.
Oaklins Cavendish’s sister firm finnCap, based in the UK, advised Open Orphan Plc on its oversubscribed equity fundraising of US$15.5 million.
Talk to the deal team
PartnerLondon, United Kingdom
Laptaria cu Caimac has completed an IPO
Laptaria cu Caimac has raised US$5 million through a private placement of shares on the ATS Market of BSE. The funds will be used for the development of the factory, namely, the construction of a bottle and jar washing station, utility systems and packaging storage.Learn more
Nutricare has raised 3.1 million via an entitlement offer
Nutricare Pty Ltd has raised funds to support its growth strategy.Learn more
Alexandria Pankkiiriliike Oyj has raised US$9.7m in the course of its IPO on NASDAQ First North Finland
Alexandria Pankkiiriliike Oyj (Alexandria) has raised US$9.7 million in the course of its IPO.Learn more